300
Views
7
CrossRef citations to date
0
Altmetric
REVIEW

Glutamatergic Modulators: The Future of Treating Mood Disorders?

, MD, , MD, PhD, , MA, , MD, , MD, MS & , MD
Pages 293-303 | Received 28 Aug 2009, Accepted 18 Feb 2010, Published online: 08 Sep 2010

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (7)

Gabriele Sani, Georgios D. Kotzalidis, Federica Fiaschè, Giovanni Manfredi & S. Nassir Ghaemi. (2022) Second messengers and their importance for novel drug treatments of patients with bipolar disorder. International Review of Psychiatry 34:7-8, pages 736-752.
Read now
Nefize Yalin & Allan H Young. (2020) Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?. Neuropsychiatric Disease and Treatment 16, pages 1459-1472.
Read now
Fernanda S Correia-Melo, Felipe C Argolo, Lucas Araújo-de-Freitas, Gustavo Carneiro Leal, Flávio Kapczinski, Acioly Luiz Lacerda & Lucas C Quarantini. (2017) Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review. Neuropsychiatric Disease and Treatment 13, pages 1627-1632.
Read now
Rodrigo Machado-Vieira, Marcio G. Soeiro-De-Souza, Erica M. Richards, Antonio L. Teixeira & Carlos A. Zarate$suffix/text()$suffix/text(). (2014) Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: Developing treatments using an integrated translational approach. The World Journal of Biological Psychiatry 15:2, pages 84-95.
Read now
Mesut Cetin & Feyza Aricioglu. (2013) Unmet needs in psychiatry and emerging novel pharmacological agents. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 23:3, pages 199-204.
Read now
Kevin Ryan Connolly & Michael E Thase. (2012) Emerging drugs for major depressive disorder. Expert Opinion on Emerging Drugs 17:1, pages 105-126.
Read now
Kenji Hashimoto. (2011) Role of the mTOR signaling pathway in the rapid antidepressant action of ketamine. Expert Review of Neurotherapeutics 11:1, pages 33-36.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.